Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | LCAT | P04180 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | OGA | O60502 | 6/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23296834 | 0.98 | IDH2 (0.47) | IDH2KDM4EABL1LMNALCAT | |
| SCHEMBL21624807 | 0.90 | CAMK1D (0.45) | IDH2KDM4EABL1LMNAKCNH2 | |
| SCHEMBL21624806 | 0.90 | CAMK1D (0.45) | IDH2KDM4EABL1LMNAKCNH2 | |
| SCHEMBL12412568 | 0.83 | PTPN11 (0.40) | IDH2GPR119PTPN11 | |
| SCHEMBL355858 | 0.83 | LCAT (0.48) | IDH2KDM4EABL1LMNALCAT | |
| SCHEMBL19741318 | 0.82 | HRH4 (0.44) | OGACHRM2 | |
| SCHEMBL20064015 | 0.80 | SIGMAR1 (0.45) | CYP3A4PTPN11 | |
| SCHEMBL24968333 | 0.80 | OGA (0.46) | IDH2KDM4ELCATOGACXCR3 | |
| Hydrochloric Acid SCHEMBL31381926 | 0.79 | LMNA (0.47) | KDM4EABL1LMNAPARP1CHRM2 | |
| SCHEMBL23296939 | 0.79 | OGA (0.41) | LCATCYP3A4OGAGPR119PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-07-04 | — | — | US | disclosed |
| WO-2023185073-A1 | PARP7 INHIBITOR AND USE THEREOF | 诺沃斯达药业(上海)有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023001247-A1 | PYRIDAZINONE COMPOUND | 南京明德新药研发有限公司 | 2023-01-26 | — | — | WO | disclosed |
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-05-06 | — | — | US | disclosed |
| WO-2021087025-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | F11, F12, ZYX | IDH2 3553/4885KDM4E 3028/4885ABL1 2789/4885 |
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | IDH2 337/4885KDM4E 929/4885ABL1 1004/4885 |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | PARP2, PARP1, PARP4 | IDH2 211/4885KDM4E 1264/4885ABL1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.